Loading
A phase 2 trial of Amivantamab, Lazertinib, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06667076 by Janssen Research & Development, LLC, with 480 participants planned, started 2024-12-16 and due to reach its primary completion in 2029-05-23. Interventions recorded: Amivantamab, Lazertinib, Chemotherapy: Pemetrexed and Chemotherapy: Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/